300 results on '"Etzion, Ohad"'
Search Results
2. Hepatitis D Virus and HBsAg Dynamics in the era of new Antiviral Treatments
3. MELD-Na score may underestimate disease severity and risk of death in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
4. Dynamic Elevation of Aromatic Amino Acids in Hepatitis C Virus-Induced Cirrhosis After a Standard Meal
5. Longitudinal multi-omics analyses of the gut–liver axis reveals metabolic dysregulation in hepatitis C infection and cirrhosis
6. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
7. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries
8. Liver Cirrhosis, Etiology and Clinical Characteristics Disparities Among Minority Population
9. Liver cirrhosis in elderly patients: clinical characteristics, complications, and survival—analyses from a large retrospective study
10. THU-364 Modeling suggests that undetectable HCV at week 2 of DAA therapy could identify patients for shorter treatment duration
11. WED-382 Modeling dual antiviral activity of lonafarnib to explain hepatitis D virus RNA negativity 24 weeks after end of therapy despite RNA positivity at end of therapy: The D-LIVR study
12. OS-034 Safety and efficacy of REP 2139-Mg in hepatitis D patients with advanced liver disease: an international compassionate use program
13. Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma
14. HepQuant SHUNT Detects Portal Hypertension in Early Stages of Clinically Compensated Chronic Liver Disease
15. Novel proteomic signatures may indicate MRI-assessed intrahepatic fat state and changes; the DIRECT PLUS clinical trial
16. Dynamic Elevation of Aromatic Amino Acids in Hepatitis C Virus-Induced Cirrhosis After a Standard Meal
17. Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy
18. Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis
19. Characterization of Hepatic Dysfunction in Subjects Diagnosed With Chronic GVHD by NIH Consensus Criteria
20. Circulating isomiRs May Be Superior Biomarkers Compared to Their Corresponding miRNAs: A Pilot Biomarker Study of Using isomiR-Ome to Detect Coronary Calcium-Based Cardiovascular Risk in Patients with NAFLD.
21. Interferon alpha induces a stronger antiviral effect than interferon lambda in HBV/HDV infected humanized mice
22. Non‐selective dampening of the host immune response after hepatitis C clearance and its association with circulating chemokine and endotoxin levels
23. Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents
24. Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study
25. Week 48 results of the phase 3 D-LIVR study, a randomized double-blind, placebo-controlled trial evaluating the safety and efficacy of Lonafarnib-boosted with Ritonavir with or without Peginterferon Alfa in patients with chronic hepatitis delta
26. Comorbidities and Malignancy among NAFLD Patients Compared to the General Population, A Nation-Based Study
27. A Simple, Rapid, and Effective Heparinase Protocol to Enable Nucleic Acid Study from Frozen Heparinized Plasma.
28. Incidence rates and clinical characteristics of primary gastrointestinal non-Hodgkin lymphoma: a population study
29. Treatment of chronic hepatitis D with peginterferon lambda—the phase 2 LIMT-1 clinical trial
30. Response-guided hepatitis C treatment during pregnancy and postpartum
31. Longitudinal multi-omics analyses of the gut–liver axis reveals metabolic dysregulation in hepatitis C infection and cirrhosis
32. Modeling the Interplay between HDV and HBV in Chronic HDV/HBV Patients
33. Improving the Treatment Response of Patients with Irritable Bowel Syndrome: Implementing a Second-Generation Artificial Intelligence System for Overcoming Resistance
34. The impact of the COVID-19 pandemic on colorectal and gastric cancer diagnosis, disease stage and mortality
35. Clinical features predictive of cirrhosis in a large cohort of patients with chronic hepatitis delta infection- Insights from the D-LIVR trial
36. Simplifying mathematical-based response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients
37. Mathematical modeling of HDV RNA kinetics suggests high peginterferon Lambda efficacy in blocking viral production: insights from the LIMT-1 study
38. Strong correlation between HBsAg, ALT and HDV-RNA levels in patients with chronic hepatitis D. Results of phase 3 D-LIVR study.
39. Comorbidities and malignancy among NAFLD patients compared to general population
40. Lonafarnib combination with peginterferon Lambda diminished triphasic HDV kinetic pattrn seen under Lambda monotherapy: the LIFT HDV study
41. A Misleading Pattern of Serologic Findings During Hepatitis B Virus Infection
42. Postprandial Plasma Lipidomics Reveal Specific Alteration of Hepatic-derived Diacylglycerols in Nonalcoholic Fatty Liver Disease
43. Chronic hepatitis C: Diagnosis and treatment made easy
44. Abnormal liver tests are not sufficient for diagnosis of hepatic graft‐versus‐host disease in critically ill patients
45. WED-407 Characterization of hepatitis D virus RNA and hepatitis B surface antigen kinetics during pegylated interferon-alphamonotherapy: The D-LIVR study
46. Sa1636 NON-INVASIVE TESTING IN CHRONIC HEPATITIS D VIRUS (HDV) INFECTION: WHAT WORKS BEST TO RULE OUT CIRRHOSIS?
47. Sa1647 DIFFERENTIAL EXPRESSION OF HEPATIC NUCLEAR MITOCHONDRIA ASSOCIATED GENES FOLLOWING HEPATITIS C CLEARANCE AND THEIR RELATIONSHIP WITH CIRCULATING AND PORTAL CHEMOKINE LEVELS
48. Modeling-Based Response-Guided Hepatitis C Treatment During Pregnancy and Postpartum.
49. Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration
50. Machine learning for mathematical models of HCV kinetics during antiviral therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.